In:
Cancer, Wiley, Vol. 100, No. 7 ( 2004-04), p. 1498-1506
Abstract:
As a potentially less toxic alternative to combination regimens involving high‐dose ifosfamide (IF) plus doxorubicin (DX) for the treatment of advanced soft tissue sarcoma, the authors designed a sequential, dose‐dense schedule of DX and IF and explored its feasibility and toxicity, as well as patient compliance with the schedule, in a Phase II trial. At the completion of treatment, the mean dose intensities for DX and IF were 40 mg/m 2 per week and 3.87 g/m 2 per week, respectively. Sixty‐six percent of patients completed the regimen projected by the protocol, and 20 of 53 assessable patients achieved objective responses, with a median time to progression of 24 weeks.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2004
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Bookmarklink